Clinical Trials Logo

Clinical Trial Summary

The aim of the present study is to evaluate safety and efficacy of gastric lavage with paraffin oil or gastric lavage with coconut oil in management of acute Aluminum phosphide poisoning.


Clinical Trial Description

60 patients will be randomly assigned as control groups, paraffin group, and coconut group in a 1:1:1 ratio (30 patients in each group). Inclusion criteria: - Patients with symptomatic acute aluminum phosphide poisoning - Age is more than 12 years of both gender - Patients presenting within 6 hours post-ingestion of aluminum phosphide (Papade and Vanjari, 2019). The diagnosis is made on the basis of: 1. The suggestive clinical manifestations due to and following shortly after a single exposure to aluminum phosphide. 2. Reliable identification of the compound based on the container brought by patient attendants. 3. Biochemical detection of phosphine gas in gastric aspirate (silver nitrate test). - Group (I): Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube (Control group) - Group (II): Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube (Paraffin group). - Group (III): Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube (Coconut group). - All patients will continue to receive the standard supportive treatment according to Tanta University Poison Control Center protocol, which is determined by the attending physician who maintains clinical responsibility for all patients. Conventional standard treatment included using inotropes, fluids and electrolytes resuscitation, intubation, mechanical ventilation and antiarrhythmic agents if indicated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04724655
Study type Interventional
Source Tanta University
Contact
Status Completed
Phase Early Phase 1
Start date January 1, 2021
Completion date September 15, 2021

See also
  Status Clinical Trial Phase
Completed NCT05215444 - Evaluation of Some Prognostic Factors in Acute Aluminum Phosphide Intoxicated Cases
Not yet recruiting NCT04702906 - Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity N/A